AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
US-based AbbVie (NYSE: ABBV) has announced the European Commission (EC) approval for its antibody drug...
AbbVie
AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of...
AbbVie Reports Q3 2024 Revenue Growth, Strength in Immunology and Neuroscience
US pharmaceutical company AbbVie (NYSE: ABBV) has announced its financial results for the third quarter...
AbbVie Inks $1.4 Billion Deal to Acquire Alzheimer’s Drug Developer Aliada Therapeutics
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a definitive agreement to acquire all...
AbbVie and Gedeon Richter Expand Partnership to Develop Novel Neuropsychiatric Targets
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing...
AbbVie’s Vyalev Wins FDA Approval as First Subcutaneous Levodopa Therapy for Advanced Parkinson’s
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the US, has received approval from...
NMPA Clears AbbVie’s ABBV-706 for Clinical Trials Targeting SCLC and Neuroendocrine Tumors
The China National Medical Products Administration (NMPA) has granted clinical trial approval to ABBV-706, a...
AbbVie Submits First BLA for c-Met Targeting ADC Telisotuzumab Vedotin to FDA
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company in the U.S., has announced the filing...
AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute
AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie...
AbbVie Completes Acquisition of Cerevel Therapeutics in $8.7 Billion Deal
US pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has announced the successful completion of its acquisition...
AbbVie’s Allergan Aesthetics Wins NMPA Approval for Juvéderm Dermal Filler in China
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National...
AbbVie’s Q2 2024 Results Show Resilience Amid Humira Biosimilar Challenges
AbbVie Inc. (NYSE: ABBV) has reported its financial results for the second quarter of 2024,...
Sionna Therapeutics Secures Cystic Fibrosis Portfolio in Licensing Deal with AbbVie
US-based biotechnology company Sionna Therapeutics has announced a significant licensing agreement with fellow US firm...
Pfizer and AbbVie Announce Leadership Changes in Global R&D Divisions
In significant executive reshuffling, Pfizer Inc. (NYSE: PFE) and AbbVie (NYSE: ABBV) have both announced...
Genmab and AbbVie’s Epcoritamab Earns FDA Accelerated Approval for Follicular Lymphoma
Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, and its co-development partner AbbVie (NYSE: ABBV),...
AbbVie Bolsters Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition
AbbVie (NYSE: ABBV), a major U.S. pharmaceutical company, has announced the acquisition of Celsius Therapeutics...
AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio
AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved...
AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer
Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000...
AbbVie Strikes Deal with FutureGen for Global Rights to Next-Gen TL1A Antibody FG-M701
AbbVie (NYSE: ABBV), a biopharmaceutical giant based in the US, has announced a licensing agreement...